A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
Quinoline inhibitors are appealing medicinal products for a range of illnesses and problems. It is bicyclic heterocyclic scaffold has been intensively employed in pharmacological research and is well known for its wide range of biological purposes. Biological activities exhibited by quinoline derivatives, such as anti-inflammatory properties, antioxidant, antimicrobial, anti-tubercular, antidiabetic, anti-malarial and others are covered in detail in this review. The IC50 of patented inhibitors might range from nm to μM range, based on the experiments used. It presents an outline of patents file between 2002 and 2023 concerning to biological activities by quinoline derivatives. As a result, it is critical to develop additional chemical quinoline core alterations for novel chemical compounds and enhanced pharmacological impacts.
Aim: the activity of patent claims by Mexican pharmaceutical companies is unknown. Objective: analyse the trend in patents of Mexican pharmaceutical companies. Method: a search for patents was carried out in the patent database of the Mexican Institute of Industrial Property, using the list of Mexican pharmaceutical companies belonging to the Mexican Association of Pharmaceutical Research Industries, and the codes A61K, A61P and C07 of the International Patent Classification. Results: the leading companies in patent applications were Liomont, Senosiain and RIMSA; however, Mexican pharmaceutical companies claim very few patents, only 266 patent applications in the period 2000-2020, with a technological factor with a value of zero, and a commercial factor of little value. Conclusion: Mexican pharmaceutical companies lack a robust patent system, without growth, and with a low percentage of patents with high commercial value.
Pancreatic adenocarcinoma, a devastating disease, has the worst cancer prognosis in humans. It often develops resistance to common chemotherapy medications, such as gemcitabine, taxol and 5-fluorouracil. The dense stroma limits therapeutic efficacy in treating this disease. Low or limited drug loading capacity is another problem with current chemotherapeutic agents. There is a need to develop novel approaches to overcome these issues. Hence, an innovative approach has been proposed to co-deliver both hydrophilic (Gemcitabine) and hydrophobic (Paclitaxel) drugs in a single carrier using lipid bilayer-mesoporous silica nanoparticles (LB-MSNP). MSNPs offer effective drug delivery due to their superior bioavailability and physicochemical properties. Further, in order to achieve clinical translation and regulatory approval, toxicity and biodegradability of MSNPs must be resolved.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：